Macular oedema: the measurements that count

Article

Thickness measurements of the central macular region can be used to differentiate between eyes with and without diffuse clinically significant macular oedema (CSMO), but not between eye with or without foveal CSMO, according to a study published in the February issue of Acta Ophthalmologica Scandinavia.

Thickness measurements of the central macular region can be used to differentiate between eyes with and without diffuse clinically significant macular oedema (CSMO), but not between eye with or without foveal CSMO, according to a study published in the February issue of Acta Ophthalmologica Scandinavia.

Lars Loumann Knudsen from the Aarhus University Hospital, Aalborg, Denmark, conducted a study that included 47 normal subjects and 158 ocular examinations of 38 eyes from 22 diabetic subjects with and without CSMO. The central macular region was subdivided into narrow concentric rings around the foveola and the thickness of the individual concentric rings were calculated. Sensitivity and specificity of the CSMO diagnosis were established using the average thickness and the thickness of the concentric rings.

It was found that the average thickness of the central macular region was 165.1 µm in the normal subjects and 192.3 µm in eyes without CSMO. The thickness increased significantly to 198.2 µm in eyes with foveal CSMO and 236.9 µm in eyes with diffuse CSMO. Sensitivity for focal CSMO was 48% with average thickness measurements and 83.6% with concentric rings. The corresponding values for detection of diffuse CSMO were 91.7% and 96.1%, respectively. Specificity was 77.4% with average thickness measurements and 79.7% with concentric rings.

Knudsen concluded that, although thickness measurements can be used to distinguish between eyes with and without diffuse CSMO, it is not as effective at distinguishing between eyes with and without foveal CSMO. He added that sub–analysis based on concentric rings around the foveola does seem to be a useful clinical tool for increasing diagnostic certainty.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.